Free Trial
NASDAQ:TYRA

Tyra Biosciences Q3 2023 Earnings Report

Tyra Biosciences logo
$12.37 -0.51 (-3.96%)
Closing price 04:00 PM Eastern
Extended Trading
$12.37 0.00 (0.00%)
As of 06:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tyra Biosciences EPS Results

Actual EPS
-$0.49
Consensus EPS
-$0.35
Beat/Miss
Missed by -$0.14
One Year Ago EPS
N/A

Tyra Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Tyra Biosciences Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Tuesday, November 7, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Tyra Biosciences' Q3 2025 earnings is scheduled for Thursday, November 6, 2025

Tyra Biosciences Earnings Headlines

Tyra Biosciences' (TYRA) "Buy" Rating Reaffirmed at HC Wainwright
Brokerages Set Tyra Biosciences, Inc. (NASDAQ:TYRA) PT at $30.83
Small Washington, DC Group Could Crash US Stocks
New Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split the entire U.S. market in two on or before Sept 30, causing a crisis "many times worse than 2008."tc pixel
See More Tyra Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tyra Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tyra Biosciences and other key companies, straight to your email.

About Tyra Biosciences

Tyra Biosciences (NASDAQ:TYRA), a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

View Tyra Biosciences Profile

More Earnings Resources from MarketBeat